Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 19/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 2/20 | 1.00 |
| ▸ | TCF7 | P36402 | 2/20 | 1.00 |
| ▸ | BCL9 | O00512 | 1/20 | 1.00 |
| ▸ | TCF4 | P15884 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833048 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13744871 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865605 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL178745 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677335 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865597 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677334 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL18699677 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL19833044 | 0.94 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL20752946 | 0.94 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 688 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025251988-A9 | REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF | 广州国家实验室 | 2026-05-15 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-10 | — | — | US | claimed |
| EP-4346928-B1 | BIODEGRADABLE TISSUE SCAFFOLD WITH SECONDARY MATRIX TO HOST WEAKLY ADHERENT CELLS | US HEALTH (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2025262235-A1 | UNGULATE PLURIPOTENT STEM CELL CULTURE MEDIUM | MEAT TOMORROW APS (DK) | 2025-12-26 | — | — | WO | claimed |
| US-12503685-B2 | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-12-23 | — | — | US | claimed |
| US-12486495-B2 | Cardiac organoid, manufacturing method therefor, and method for evaluating drug toxicity by using same | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2025-12-02 | — | — | US | claimed |
| EP-4627061-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12391919-B2 | Culture medium, coating matrix and method for maturing midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-08-19 | — | — | US | claimed |
| WO-2022051847-A9 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | UNIVERSITY HEALTH NETWORK (CA) | 2022-04-21 | — | — | WO | claimed |
| CN-114369577-A | Cattle induced expansion pluripotent adult stem cell, line establishing method and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| CN-114369567-A | Method for establishing bovine expanded pluripotent embryonic stem cells and culture solution | 内蒙古大学 | 2022-04-19 | — | — | CN | claimed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022063224-A1 | ACTIVATED PLURIPOTENT STEM CELL, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院动物研究所 | 2022-03-31 | — | — | WO | claimed |
| CN-114250195-A | Activated pluripotent stem cell and preparation method and application thereof | 中国科学院动物研究所 | 2022-03-29 | — | — | CN | claimed |
| CN-114209837-A | Medicine for treating erectile dysfunction and application thereof | 中山大学附属第五医院 | 2022-03-22 | — | — | CN | claimed |
| WO-2022051847-A1 | METHODS FOR GENERATING NEURAL PROGENITOR CELLS WITH A SPINAL CORD IDENTITY | UNIVERSITY HEALTH NETWORK (CA) | 2022-03-17 | — | — | WO | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570956-B2 | Efficient derivation of stable pluripotent bovine embryonic stem cells | WNT1, PHKA1, ACVR1 | CLPP 3412/4885CTNNB1 23/4885TCF7 721/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | CLPP 3443/4885CTNNB1 8/4885TCF7 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.